Certifications & Patents


"Global product patent in the United States, Singapore, S. Africa, India recognized innovation that will eventually help 108 diseases and create employment for millions of people"


14.Companies That Infringe Biomix Patents
:
Europian Patent Certificate
:
Entry Barrier via Global Patent Exclusivity
:
Grant Certificate - US
:
Granted Certificate - South Africa
:
Original Certificate - Singapore
:
Patents brief
:
Patent documents
:
Singapore Patent Description
:
Issue Notification US Patent
:
Registration certificate    
 
  Australia
  Singapore
  South Africa
  Kenya
Lab On Chip
:
List of PCT Contracting States - Dec. 2015
:
HDL006 Poter & Clarkson--PCT-IN09-749
:
HDL006 Poter & Clarkson--PCT-IN09-749 (2)
:
Lab on Chip ( PCT International Application )
:
Hospital on Chip (International Publication with ISR)
:
Hospital on Chip (Later publication of amended claims under Article 19)
:
Hospital On Chip Information
:

Biography and granted Global Patents

Global patents and certifications listed below are a proof for acceptance of our innovation

Dr. Pawan Saharan, Founder CEO of Biomix in India, USA, UK has a vision to provide Health for All, invented World's 1st solution to H1N1, HIV and host of other Immunity problems via Discovery of A Broad Spectrum Antiviral and New Generation Immuno-modulator- RECEPTOL® after years of Research & Clinical Studies in the United States, Africa & India in collaboration with Dept. of Science & Technology, GoI New Drug Discovery Program with an Award of INR 120M.

Dr. Saharan created the World's 1st Nano-Bio-IT Helix via inventing Globally Patented Radha 108 Nano - Peptides from colostrum. Mother's 1st Milk after the birth of child to formulate RECEPTOL® oral spray with an application in 56 fatal disease.

Dr. Saharan was granted global Product Patents for Radha 108 Receptol with US product Patent # US 8,518,454 B2; (For treatment of HIV & 56 other disease); South Africa Patent # 2011/04687; Singapore patent # 172793; European Patent Application #. 09827010.1; Indian patent application #. 1353/MUM/2008.

Canadian Govt. invited Dr. Saharan as the state guest in recognition for his Contribution to healthcare and technological alliances between North America and India via Canada India Business Council

UK Prime Minister invited Dr. Saharan in March, 2011 as a key note speaker at the UK India Business Council for the key note talk on affordable health care.American Association for the Advancement of Science (AAAS), Washington DC nominated Dr. Saharan for the best US Graduate Student Scientist Award.

Bhaktivedanta Institute in California, USA published several books by Dr Saharan on Science & Spirituality-including Interviews with Seven prominent Nobel Laureates, Prof. Charles H. Townes, Inventor of Laser, University of California, Berkley et. al. Dr. Saharan has been the President of ISKCON in USA and India and contributed to global peace initiative at UN forums.



 References for Biological activities
»
Bonavida B Immunomodulatory effect of tumor necrosis factor. Biotherapy 3: 127-33 (1991);
»
Brouckaert P et al Tumor necrosis factor, its receptors and the connection with interleukin 1 and interleukin 6. Immunobiology 187: 317-29 (1993)
»
Camussi G et al The molecular action of tumor necrosis factor-alpha. European Journal of Biochemistry 202: 3-14 (1991)
»
Cordingley FT et al Tumor necrosis factor as an autocrine tumor growth factor for chronic B cell malignancies. Lancet I: 969-71 (1988)
»
Frater-Schröder M et al Tumor necrosis factor type a, a potent inhibitor of endothelial cell growth in vitro is angiogenic in vivo. Proceedings of the National Academy of Science (USA) 84: 5277-81 (1987)
»
Goillot E et al Tumor necrosis factor as an autocrine growth factor for neuroblastoma. Cancer Research 52: 3194-200 (1992)
»
Grunfeld C and Feingold KR The metabolic effects of tumor necrosis factor and other cytokines. Biotherapy 3: 143-58 (1991)
»
Larrick JW and Wright SC Cytotoxic mechanism of tumor necrosis factor-alpha FASEB Journal 4: 3215-32 (1990)
»
Larrick JW and Kunchel SL The role of tumor necrosis factor and interleukin in the immuno-inflammatory response. Pharm. Research 5: 129-39 (1988)
»
Last-Barney K et al Synergistic and overlapping activities of tumor necrosis factor-alpha and IL1. Journal of Immunology 141: 527-30 (1988)
»
Merrill JE Effects of Interleukin 1 and tumor necrosis factor alpha on astrocytes, microglia, oligodendrocytes, and glial precursors in vitro. Dev. Neurosci. 13: 130-7 (1991)
»
Nacy CA et al Tumor necrosis factor-alpha: Central regulatory cytokine in the induction of macrophage antimicrobial activities. Pathobiology 59: 182-4 (1991)
»
Perez C et al A nonsecretable cell surface mutant of tumor necrosis factor (TNF) kills by cell-to-cell contact. Cell 63: 251-8 (1990)
»
Sato N et al Actions of TNF and IFN-gamma on angiogenesis in vitro. Journal of Investigative Dermatology 95: 85S-9S (1990)
»
Schiller JH et al Tumor necrosis factor, but not other hematopoietic growth factors, prolongs the survival of hairy cell leukemia cells. Leukocyte Research 16:337-46 (1992)
»
Schulze-Osthoff K et al Depletion of the mitochondrial electron transport abrogates the cytotoxic and gene-inductive effects of TNF EMBO Journal 12:3095-3104 (1993)
»
Tartaglia LA et al The two different receptors for tumor necrosis factor mediate distinct cellular responses. Proceedings of the National Academy of Science (USA) 88: 9292-6 (1991)
»
Trinchieri G Effects of TNF and lymphotoxin on the hematopoietic system. Immunology Ser. 56: 289-313 (1992)

“Those who dream big only have the capability to achieve big”. We dreamt of making our mother earth free from diseases and in this path we finally innovated Receptol."


Copyright © BIOMIX NETWORK LTD